Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrenceMay 25, 2018
1. In this randomized controlled trial, time to recurrence was lower in patient with non-muscle-invasive urothelial cancer when treated with intravesical gemcitabine as compared to saline controls. 2. There was no difference in all-cause mortality between the two treatment groups. Evidence Rating: 1 (Excellent) Study Rundown: Non-muscle-invasive urothelial cancer is the most common form of 
Study results support the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer.
Enfortumab vedotin was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA), based on interim results from a Phase 1 study.
Patients on hemodialysis that underwent radical cystectomy for bladder cancer experienced increased mortality.
Researchers assessed the use of cfDNA-based liquid biopsy to guide and expedite clinical trial enrollment for patients with with metastatic urothelial carcinoma.
A meta-analysis indicates that a history of urinary calculi could increase a person's risks for developing bladder cancer.
The presence of CKD may increase chances for poor outcomes following radical cystectomy for urothelial carcinoma of the bladder.
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
Tool incorporates the relative contribution of tumor stage and lymph node involvement.
Approximately 50% of patients with advanced urothelial carcinoma are unable to receive standard first-line cisplatin-based chemotherapy, indicating a need for additional treatment options.
Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.
Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.
Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.
US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.
Researchers believe arsenic exposure might contribute to higher-than-normal rates of bladder cancer in the region.
Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.
A bladder preservation rate of 83% occurred at 3 years after a trimodality treatment approach for localized bladder cancer that used adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT).
Guideline on muscle-invasive and metastatic bladder cancer, with qualifying statements
Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.
Adjuvant chemotherapy was associated with improved survival in patients with locally advanced bladder cancer.
Mental health status prior to bladder cancer surgery may be associated with postoperative outcomes.
A novel immunotherapeutic approach improved outcomes for patients with advanced bladder cancer, according to a recent study.
Researchers developed a way to personalize treatments for aggressive bladder cancer. Taking bladder tumors from individual patients, identifying actionable mutations, and grafting the tumors into mice, researchers were able to simultaneously test multiple therapies in the tumor models.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|